1. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

2. Disclosures Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

3. Study Rationale Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

4. Study 303: Study Schema Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

5. Patient Characteristics Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

6. Primary Endpoint: Kaplan-Meier Estimate of PFS Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

7. PFS by Previous VEGF-Targeted Therapy Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

8. PFS Subgroup Analyses Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

9. Response Rates Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

10. Best Tumor Response Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

11. Overall Survival, ITT population Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

12. Study Medication Exposure Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

13. Treatment-emergent Adverse Events (TEAEs) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

14. Most Frequent Treatment-related Adverse Events (> 20%) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

15. TEAEs of Special Interest Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

16. Conclusions Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

17. Slide 17 Presented By Martin Schlumberger at 2014 ASCO Annual Meeting